Evaluation of the EUROIMMUN Aspergillus antigen immunoenzyme assay in serum and bronchoalveolar lavage fluid samples
| Autor: | Noelia Ahedo-García, Carlos Ruiz de Alegría-Puig, Ana de Malet Pintos-Fonseca, María Pía Roiz-Mesones |
|---|---|
| Rok vydání: | 2023 |
| Předmět: |
Microbiology (medical)
medicine.medical_specialty medicine.diagnostic_test business.industry General Medicine Aspergillosis medicine.disease Serum samples Gastroenterology Immunoenzyme assay Galactomannan chemistry.chemical_compound Bronchoalveolar lavage chemistry Internal medicine Aspergillus antigen medicine business |
| Zdroj: | Enfermedades Infecciosas y Microbiología Clínica. 41:176-180 |
| ISSN: | 0213-005X |
| DOI: | 10.1016/j.eimc.2021.08.011 |
| Popis: | Introduction The most widely used marker for the diagnosis of invasive aspergillosis (IA) is the detection of galactomannan by ELISA. This study describes the evaluation of the results obtained by Euroimmun Aspergillus antigen ELISA (EIA-GM-E) in serum samples and bronchoalveolar lavage fluid (BAL) from patients at risk of IA, and compares these results with those obtained by Bio-Rad Galactomannan EIA (EIA-GM-BR). Methods Anonymous retrospective case–control comparative study in 64 serum samples and 28 BAL from 51 patients. Results Overall agreement of the results of the two assays was observed in 72 of 92 samples (78.3%). The sensitivity of EIA-GM-BR and EIA-GM-E in serum samples was 88.9% and 43.2%, respectively, and 100% and 88.9% for BAL. The specificity of EIA-GM-BR and EIA-GM-E in serum samples was 91.9% for both assays, and 68.4% and 84.2% in BAL. There were no statistically significant differences in the results of both assays. Conclusions Both methods show good results for the discrimination of patients with IA when BAL is tested, or serum in case of EIA-GM-BR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|